ZNTL
Income statement / Annual
Last year (2023), Zentalis Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Zentalis Pharmaceuticals, Inc.'s net income was -$292.19 M.
See Zentalis Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$14,000.00
|
| Cost of Revenue |
$1.39 M |
$1.43 M |
$544,000.00 |
$160,000.00 |
$111,000.00 |
$0.00 |
| Gross Profit |
-$1.39 M |
-$1.43 M |
-$544,000.00 |
-$160,000.00 |
-$111,000.00 |
$14,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
1 |
| Research and Development
Expenses |
$235.16 M
|
$172.73 M
|
$175.60 M
|
$84.90 M
|
$38.39 M
|
$18.92 M
|
| General & Administrative
Expenses |
$59.40 M
|
$54.55 M
|
$40.94 M
|
$33.89 M
|
$8.46 M
|
$4.88 M
|
| Selling & Marketing
Expenses |
-$1.39 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$59.40 M
|
$54.55 M
|
$40.94 M
|
$33.89 M
|
$8.46 M
|
$4.88 M
|
| Other Expenses |
$45.57 M |
$0.00 |
$0.00 |
$0.00 |
-$16,000.00 |
$0.00 |
| Operating Expenses |
$302.37 M |
$227.29 M |
$216.54 M |
$118.79 M |
$46.85 M |
$23.80 M |
| Cost And Expenses |
$302.37 M |
$227.29 M |
$216.54 M |
$118.79 M |
$46.85 M |
$23.80 M |
| Interest Income |
$0.00 |
$2,262.00 |
$1,309.00 |
$1,239.00 |
$498,000.00 |
$355,000.00 |
| Interest Expense |
$0.00 |
$2.58 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.39 M
|
$1.43 M
|
$544,000.00
|
$160,000.00
|
$111,000.00
|
$51,491.00
|
| EBITDA |
-$247.60 M
|
-$233.27 M
|
-$268.53 M
|
-$119.47 M
|
-$46.73 M
|
-$23.73 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
-1695.14 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
-1698.79
|
| Total Other
Income/Expenses Net |
-$43.92 M
|
$5.99 M
|
$51.98 M
|
$683,000.00
|
$482,000.00
|
$355,000.00
|
| Income Before Tax |
-$292.91 M |
-$221.30 M |
-$164.56 M |
-$118.10 M |
-$46.36 M |
-$23.43 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
-1673.43
|
| Income Tax Expense |
$601,000.00 |
-$469,000.00 |
-$297,000.00 |
$444,000.00 |
$15,000.00 |
$4,000.00 |
| Net Income |
-$292.19 M |
-$220.83 M |
-$164.26 M |
-$118.55 M |
-$46.38 M |
-$21.07 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
-1504.79 |
| EPS |
-4.47 |
-4.18 |
-3.85 |
-2.89 |
-1.29 |
-1.17 |
| EPS Diluted |
-4.47 |
-4.18 |
-3.85 |
-2.89 |
-1.29 |
-1.17 |
| Weighted Average Shares
Out |
$65.41 M
|
$52.86 M
|
$42.69 M
|
$41.04 M
|
$35.88 M
|
$18.06 M
|
| Weighted Average Shares
Out Diluted |
$65.41 M
|
$52.86 M
|
$42.69 M
|
$41.04 M
|
$35.88 M
|
$18.06 M
|
| Link |
|
|
|
|
|
|
